Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare (ALHC) — insider transaction: CEO and director John E. Kao, via the JEK Trust, sold 180,000 shares of common stock on 11/10/2025 at a weighted-average price of $16.3154. The sale was made under a Rule 10b5-1 trading plan adopted on 03/12/2025.
After the transaction, Mr. Kao beneficially owns 2,526,726 shares indirectly through the JEK Trust and 2,839,942 shares directly.
Alignment Healthcare (ALHC) reported Q3 2025 results showing strong top-line growth and a return to profitability. Revenue rose to $993.7 million from $692.4 million a year ago, driven by earned premiums of $983.7 million. Medical expenses were $868.0 million and SG&A was $110.0 million, yielding operating income of $7.7 million.
Net income was $3.7 million versus a $26.4 million loss last year, with diluted EPS of $0.02. Year-to-date, revenue reached $2.94 billion and net income was $10.0 million. Cash and cash equivalents were $618.1 million as of September 30, 2025, supported by $190.3 million of net cash provided by operating activities year-to-date. Long-term debt stood at $322.7 million (carrying value) tied to 4.25% convertible senior notes due 2029. Medical expenses payable increased to $528.8 million from $289.8 million at December 31, 2024. Shares outstanding were 199,988,515 as of September 30, 2025; as of October 27, 2025, they were 200,091,742.
Alignment Healthcare, Inc. furnished a Form 8-K to announce it issued a press release with financial results for its third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Alignment Healthcare (ALHC) director reports an open‑market sale. Joseph S. Konowiecki sold 25,000 shares of common stock on 10/28/2025 at a price of $18 per share (transaction code S(1)). Following the sale, he beneficially owns 1,085,973 shares, held directly.
The footnote indicates a Rule 10b5‑1 trading plan adopted on 03/05/2025 in connection with the sale. No derivative securities transactions were reported in this filing.
Alignment Healthcare (ALHC) CEO and director John E. Kao reported the sale of 180,000 shares of common stock on 10/10/2025 under a Rule 10b5-1 trading plan adopted on 03/12/2025.
The weighted-average sale price was $17.286, with individual trades ranging from $16.97 to $17.60. Following the transaction, beneficial ownership included 2,706,726 shares held indirectly by the JEK Trust and 2,839,942 shares held directly. A prior transfer on 09/25/2025 moved 1,693,626 shares from direct ownership to the JEK Trust.
Alignment Healthcare (ALHC) Chief Medical Officer Hyong (Ken) Kim reported two non-discretionary stock sales tied to restricted stock unit vesting and a pre-existing trading plan. On 10/08/2025 Mr. Kim sold 33,655 shares at $17.29 to cover tax withholding, leaving 413,712 shares prior to the second sale. On 10/09/2025 he sold 51,379 shares at $17.5713, leaving 362,333 shares beneficially owned after the transactions. The Form 4 notes a Rule 10b5-1 trading plan adopted on 03/14/2025, and the filings state these sales were not discretionary trades but routine tax-withholding dispositions tied to RSU vesting.
Form 144 filing for proposed sale of $908,894.51 in common stock (51,379 shares) with an approximate sale date of 10/09/2025. The shares were acquired as Restricted Stock Units on 10/04/2025 and show 51,379 units to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The filing lists 198,031,417 shares outstanding, and records prior 10b5-1 sales by the same account totaling 62,000 shares during August 2025 for aggregate gross proceeds of $946,833.62 across three trades. Certain standard issuer identification fields (issuer name and SEC file number) are not populated in the visible text, so the filing cannot be tied to an issuer by name from this extract.
Alignment Healthcare, Inc. submitted a Form 144 reporting a proposed sale of 35,500 shares of common stock, with an aggregate market value of $602,790. The shares represent a small fraction of the reported 198,031,417 shares outstanding and are scheduled for sale on 10/08/2025 on the Nasdaq Stock Market. The filing shows the securities were acquired on 10/04/2023 through the vesting of restricted stock units granted under the company’s 2021 Equity Incentive Plan. The notice also lists prior Rule 10b5-1 plan sales by the same account totaling 62,000 shares in August 2025 with combined gross proceeds of approximately $946,833. The signer certifies no undisclosed material adverse information.
Qatar Investment Authority and its subsidiary Q Healthcare Holding LLC filed a Schedule 13G reporting ownership of 13,246,096 shares of Alignment Healthcare, Inc. common stock, representing 6.69% of the outstanding shares. The filing states each reporting person has sole voting and sole dispositive power over those shares and that the percent was calculated using 198,031,417 shares outstanding per Alignment Healthcares July 25, 2025 disclosure. The statement includes a joint filing agreement and a certification that the stake was not acquired to influence control of the issuer.
General Atlantic and affiliated funds report beneficial ownership of 24,287,227 shares of Alignment Healthcare Class A common stock, representing 12.3% of the outstanding shares. The filing states the percentage is calculated using 198,031,417 shares outstanding as reported by the company in its quarterly report filed July 30, 2025. The shares are held by General Atlantic (ALN HLTH), L.P. (GA ALN) and beneficial ownership is shared across multiple General Atlantic entities and funds, with shared voting and dispositive power reported for 24,287,227 shares and no sole voting or dispositive power reported. The filing explains the intercompany relationships (general partners and managing members) that give rise to shared control and notes Michael Gosk signed on behalf of the reporting persons on September 24, 2025.